Current Issue : April - June Volume : 2017 Issue Number : 2 Articles : 6 Articles
Background: Colorectal cancer is the major cause of cancer mortality, despite development of therapeutic\nstrategies. The novel marker tumor necrosis factor receptor-associated protein 1 (TRAP1) is a mitochondrial heat\nshock protein that has been related to drug resistance and protection from apoptosis in colorectal cancer. This\nstudy aims to delineate the clinicopathologic significance of TRAP1 expression in colorectal cancer.\nMethods: Seven-hundred and fourteen FFPE tissues were collected from colorectal cancer patients who underwent\nsurgery from February 2002 to July 2011 at Dong-A University Medical Center, Busan, South Korea. We performed\nTRAP1 immunohistochemistry using tissue microarray, and divided into two groups, TRAP1 high expression group\nand low expression group. Statistical analysis was utilized to evaluate the association of TRAP1 with\nclinicopathologic characteristics and disease-specific survival of patients.\nResults: High TRAP1 expression was observed in 564 cases (79%) and low expression was 150 cases (21%). TRAP1\nexpression was significantly increased in colorectal cancer with advanced pathologic T-stage compared with that in\nearly T-stage (p = 0.008). By univariate survival analysis, high TRAP1 expression was significantly associated with worse\ndisease-specific survival (p = 0.01). But, TRAP1 expression was marginally associated with lymph node involvement and\ntumor differentiation (p = 0.085, p = 0.082, respectively). Multivariate analysis indicated that TRAP1 [removed]hazard\nratio, 1.947; 95% CI, 1.270 to 2.984; p = 0.002), and pathologic T stage (hazard ratio, 3.190; 95% CI, 1.275 to 7.983; p = 0.\n013) were independent prognostic factors for colorectal adenocarcinomas.\nConclusions: Here, we found that overexpression of TRAP1 might contribute to tumor cell local invasion of colorectal\ncancer. The association between TRAP1 overexpression and worse disease-specific survival also suggested that TRAP1\nprotein expression might have oncogenic role. Consequently, our data demonstrated that TRAP1 expression was a\ngood prognostic biomarker for depth of invasion and disease-specific survival in colorectal cancer....
Young patients with the endometrial cancer IA who desire to preserve fertility, can\nselect the conservative therapy with progestin. However, the therapy involves risks of\nprogression and relapse. We examined immunohistochemical analyses of phosphatase\nand tension homolog (PTEN) and p53 expressions to predict the early relapse,\nand pregnancy and delivery. Twenty women with endometrial cancer, FIGO IA\n(1988) (FIGO staging was essentially defined post-surgically), instead of the pathogical\nspecimen before surgery without myometrial invasion were estimated by MRI\nunder 40 years at Gifu University Hospital, Japan from 1988 to 2009. Patients were\ntreated with medroxyprogesterone acetate (MPA, 400 - 600 mg/day) for 4 - 10\nmonths, with whole wall endometrial curettage performed every four weeks. Response\nto the therapy, pregnancy, delivery and relapse of disease during follow-up\nover a 72-month period. Immunohistochemical expression of PTEN and p53 was also\nevaluated with pregnancy, delivery and relapse rate. All patients had pathological\ncomplete remissions within 4 - 10 months. Relapse rate was high (60%) in more than\n72 months. Immunohistochemical PTEN retain in tumor cells before MPA treatment\n(8/10) was significant better correlation with pregnancy and delivery rate than of lost\ncases (1/5) in non-obese women (P < 0.05). Conservative therapy is feasible in carefully\nselected young women with endometrial cancer without myometrial invasion.\nHowever, the relapse rate was high. In cases who desire to be a pregnant, an earlier\ninfertility treatment may be considered especially for PTEN loss especially in nonobese\ncases....
Background: Diffuse large B-cell lymphoma (DLBCL) typically leads to effacement of the nodal architecture by an\ninfiltrate of malignant cells. Rarely (<1%), DLBCL can present with an interfollicular pattern (DLBCL-IF) preserving the\nlymphoid follicles. It has been postulated that DLBCL-IF is derived from marginal zone B cells and may represent a\nlarge-cell transformation of marginal zone lymphoma (MZL), however no direct evidence has been provided to\ndate. Here we describe a rare case of a diagnostically challenging DLBCL-IF involving a lymph node in a patient\nwith a prior history of lymphadenopathy for several years and MZL involving skin.\nCase presentation: A 53-year old man presented to our Dermatology Clinic due to a 1-year history of generalized\nitching, fatigue of 2ââ?¬â??3 monthââ?¬â?¢s duration, nausea and mid back rash that was biopsied. PET (positron emission\ntomography)/CT (computed tomography) was performed and revealed inguinal, pelvic, retroperitoneal, axillary, and\ncervical lymphadenopathy. The patient was referred to surgery for excisional biopsy of a right inguinal lymph node.\nDiagnostic H&E stained slides and ancillary studies were reviewed for the lymph node and skin specimens. B-cell\nclonality by PCR and sequencing studies were performed on both specimens.\nWe demonstrate that this patientââ?¬â?¢s MZL and DLBCL-IF are clonally related, strongly suggesting that transformation\nof MZL to DLBCL had occurred. Furthermore, we identified a novel deletion of the long arm of chromosome 20\n(del(20q12)) and a missense mutation in BIRC3 (Baculoviral IAP repeat-containing protein 3) in this patientââ?¬â?¢s DLBCL\nthat are absent from his MZL, suggesting that these genetic alterations contributed to the large cell transformation.\nConclusions: To our knowledge, this is the first report providing molecular evidence for a previously suspected link\nbetween MZL and DLBCL-IF. In addition, we describe for the first time del(20q12) and a missense mutation in BIRC3\nin DLBCL. Our findings also raise awareness of DLBCL-IF and discuss the diagnostic pitfalls of this rare entity....
Background: Uterine serous endometrial intraepithelial carcinoma (SEIC) is an immediate precursor of invasive\ncarcinoma. The majority of stage IA SEICs are curable, but those with latent peritoneal metastasis and/or capillary\nlymphatics invasion may have poor prognoses Careful pathologic staging is thus needed to predict the risk of\nrecurrence and to determine postoperative therapeutic strategies.\nCase Presentation: A 71-year-old woman was hospitalized for the treatment of peritoneal carcinoma. She had\nundergone total hysterectomy and bilateral salpingo-oophorectomy due to SEIC (stage IA) at age 63 years, and had\nreceived medical check-ups every year since. Elevated serum CA125 (184 U/mL) was detected for the first time 8 years\nafter surgery. A thorough workup revealed no potential primary lesion other than that in the peritoneum. Tumor\nreduction surgery was performed. Histologic analysis of the peritoneal lesion was high-grade serous carcinoma. The\nperitoneal carcinoma was diffusely immunostained for p53; thus, possible recurrence of SEIC was suspected. Tumor\nDNAs were microdissected from the uterine and peritoneal lesions and p53 mutation analysis was done. SEIC and\nperitoneal carcinomas had distinct p53 mutations that were mutually exclusive.\nConclusions: The present case raised a concern about the difficulty of histologic staging for SEICs. Although\nSEICs confined to the uterine endometrium in most cases predict a good prognosis, microscopic metastasis\nto the peritoneum may not be detectable at hysterectomy. If secondary malignancies of a serous phenotype\ndevelop years later, comprehensive reexamination of SEIC is mandated, with the help of DNA analysis....
Background: Metanephric adenoma (MA) is a benign renal tumor that is difficult to distinguish from a malignant\ntumor via traditional radiography. The diagnosis of MA is often dependent on postsurgical histopathological\nexamination. In the present report, the imaging features of MA on computer tomography (CT) and magnetic\nresonance imaging (MRI) were retrospectively evaluated.\nMethods: Eight MA patients, 17ââ?¬â??67 years of age, were pathologically confirmed and recruited between April 2009\nand November 2014. Four of the eight patients were female. All patients underwent CT scanning, and one patient\nunderwent MRI scanning. Three patients underwent CTA of the renal arteries. All patients underwent resection\nsurgery (radical nephrectomy in five and nephron-sparing surgery in three patients).\nResults: The average tumor size was 44.0 Ã?± 23.6 mm. The lesions in 87.5 % cases were located both in the renal\ncortex and medulla and exhibited exophytic growth. Plain CT showed that MA tumors were solid, and the average\nCT value was 37.9 Ã?± 6.7 HU. Dynamic contrast-enhanced CT revealed that enhanced degrees of\nMA tumors in the renal cortex, renal parenchymal, and pelvic phase were all lower than that of normal renal\nparenchyma. A slight enhancement in the renal cortex phase and an even higher enhancement in the renal\nparenchymal phase were observed in seven of the cases. Progressive enhancement in the pelvic phase was found\nin five cases and a slight decreased enhancement in the pelvic phase in two cases. MRI revealed that MA tumor\nwas isointense on T1WI and isointense on T2WI with some slightly hyperintense areas in the center. CTA of the\nrenal arteries revealed the nutrient artery in one patient and no nutrient artery in two. Immunohistochemical\nexperiments demonstrated that most tumor cells were positive for vimentin, CK, and EMA.\nConclusions: MA is a rare benign renal neoplasm. Detailed knowledge of the CT and MRI characteristics of MA\nplays an important role in MA diagnosis and treatment....
Background. For development of individualized treatment on a routine basis, transfer of patientsââ?¬â?¢ tumor tissue in a xenograftmodel\n(i.e., generation of patient-derived xenografts (PDX)) is desirable for molecular, biochemical, or functional analyses. Drawbacks\nare dissatisfactory tumor take rates, the necessity of fast tumor tissue processing, and extensive logistics demanding teamwork\nof surgeons, pathologists, and laboratory researchers. Methods. The take rates of ten colorectal cancer (CRC) tissue samples in\nimmunodeficient micewere compared after direct cryopreservation and after a 24 h cooling period at 4âË?Ë?C prior to cryopreservation.\nAdditionally, the effect of simultaneous Matrigel application on the take rates was investigated. Beside take rates, tumor growth\ncharacteristics and cell culture success were analyzed. Results. Tumor takes of CRC tissue samples were significantly improved after\nMatrigel application (8 versus 15 takes, ...
Loading....